A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

NCT07694375 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Corneal Endothelial Cell Loss
Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery

Interventions

DRUG: Ophthalmic solution (matching formulation without ascorbic acid)
DRUG: Ascorbic acid ophthalmic solution 5%

Sponsor

Caravel Oculus Pty Ltd